Javier B. Szwarcberg - 10 Dec 2025 Form 4 Insider Report for SPRUCE BIOSCIENCES, INC. (SPRB)

Role: CHIEF EXECUTIVE OFFICER, Director
Signature: /s/ Samir Gharib, Attorney-in-Fact
Issuer symbol: SPRB
Transactions as of: 10 Dec 2025
Net transactions value: -$230,638
Form type: 4
Filing time: 12 Dec 2025, 19:03:14 UTC
Previous filing: 22 Oct 2025
Next filing: 15 Dec 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Szwarcberg Javier B.	CHIEF EXECUTIVE OFFICER, Director	C/O SPRUCE BIOSCIENCES, INC., 611 GATEWAY BOULEVARD, SUITE 740, SOUTH SAN FRANCISCO	/s/ Samir Gharib, Attorney-in-Fact	12 Dec 2025	0001903669

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	SPRB	Common Stock	Options Exercise	$0	+1,196	+13%	$0.000000	10,670	10 Dec 2025	Direct	F1, F2
transaction	SPRB	Common Stock	Tax liability	$36,667	-428	-4%	$85.67	10,242	10 Dec 2025	Direct	F1
transaction	SPRB	Common Stock	Options Exercise	$0	+4,950	+48%	$0.000000	15,192	11 Dec 2025	Direct	F2, F3
transaction	SPRB	Common Stock	Tax liability	$193,972	-2,194	-14%	$88.41	12,998	11 Dec 2025	Direct	F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	SPRB	Restricted Stock Units	Options Exercise	$0	-1,196	-25%	$0.000000	3,588	10 Dec 2025	Common Stock	1,196	$0.000000	Direct	F1, F2
transaction	SPRB	Restricted Stock Units	Award	$0	+19,800		$0.000000	19,800	11 Dec 2025	Common Stock	19,800	$0.000000	Direct	F2, F3
transaction	SPRB	Restricted Stock Units	Options Exercise	$0	-4,950	-25%	$0.000000	14,850	11 Dec 2025	Common Stock	4,950	$0.000000	Direct	F2, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	On March 14, 2024, the Reporting Person was granted a total of 4,784 RSU's. Subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan) as of each such vesting date, 25% of the total number of RSUs vested on December 10, 2025, the first anniversary of the achievement of a specified clinical development objective. 25% of the total number of RSUs will vest on each of the second, third and fourth anniversaries of such achievement. On December 10, 2025, 1,196 shares vested and 428 shares were withheld for taxes, resulting in a net issuance of 768 shares.
F2	Each RSU represents a contingent right to receive one share of SPRB common stock.
F3	25% of the total number of RSUs vested on grant. 25% of the total number of RSUs will vest on December 15, 2026, December 15, 2027 and December 15, 2028, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan) as of each such vesting date. On December 11, 2025, 4,950 shares vested and 2,194 shares were withheld for taxes, resulting in a net issuance of 2,756 shares.